Circulating tumor cells (CTCs) in breast cancer: A diagnostic tool for prognosis and molecular analysis

Chinese Journal of Cancer Research

Volumn 24, Issue 4, 2012, Pages 388-398

  Dong, Xiaoshen ^a,b   Alpaugh, R Katherine ^b   Cristofanilli, Massimo ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

cancer stem cells; Circulating tumor cells (CTCs); epithelial mesenchymal transition (EMT); metastatic breast cancer (MBC)

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTION FACTOR TWIST;

BONE METASTASIS; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ISOLATION; CIRCULATING TUMOR CELL; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOMAGNETIC SEPARATION; MICROARRAY ANALYSIS; NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PHENOTYPIC PLASTICITY; PROGRESSION FREE SURVIVAL; REVIEW;

EID: 84875458848     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-012-0279-4     Document Type: Review

References (66)

1. Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2012. [Epub ahead of print].
2. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
3. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
4. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-252.
5. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
6. Racila E, Euhus D, Weiss AJ, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 1998;95:4589-4594.
7. Gross HJ, Verwer B, Houck D, et al. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7). Proc Natl Acad Sci U S A 1995;92:537-541.
8. Hawes D, Neville AM, Cote RJ. Occult metastasis. Biomed Pharmacother 2001;55:229-242.
9. Hu XC, Chow LW. Detection of circulating breast cancer cells with multiple-marker RT-PCR assay. Anticancer Res 2001;21:421-424.
10. Witzig TE, Bossy B, Kimlinger T, et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002;8:1085-1091.
11. Kagan M, Howard D, Bendele T, et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 2002;25:104-110.
12. Terstappen LW, Rao C, Gross S, et al. Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast. Int J Oncol 2000;17:573-578.
13. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791.
14. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-6309.
15. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-3221.
16. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-1430.
17. Cristofanilli M, Broglio KR, Guarneri V, et al. Circulating tumor cells in metastatic breast cancer: Biologic staging beyond tumor burden. Clin Breast Cancer 2007;7:471-479.
18. Nolé F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008;19:891-897.
19. Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27:5153-5159.
20. Nakamura S, Yagata H, Ohno S, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010;17:199-204.
21. Pierga JY, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012;23:618-624.
22. Liu MC, Mego M, Nakamura S, et al. Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC). J Clin Oncol 2011;29:abstr 10592.
23. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
24. Esserman LJ, Berry DA, Demichele A, et al. Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30:3242-3249.
25. Giordano A, Giuliano M, De Laurentiis M, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012;23:1144-1150.
26. Munzone E, Botteri E, Sandri MT, et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer 2012;12:340-346.
27. Bidard FC, Mathiot C, Degeorges A, et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010;21:1765-1771.
28. Oxnard GR, Morris MJ, Hodi FS, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 2012;104:1534-1541.
29. Dawood S, Broglio K, Valero V, et al. Circulating tumor cells in metastatic breast cancer: From prognostic stratification to modification of the staging system? Cancer 2008;113:2422-2430.
30. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging: Predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-6409.
31. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F] fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 2009;27:3303-3311.
32. De Giorgi U, Mego M, Rohren EM, et al. 18F-FDG-PET/ CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 2010;51:1213-1218.
33. Mego M, De Giorgi U, Dawood S, et al. 18F-FDG PET/ CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. Int J Cancer 2011;129:417-423.
34. Powell AA, Talasaz AH, Zhang H, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012;7:e33788.
35. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-746.
36. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995;154:8-20.
37. Mani SA, Guo W, Liao MJ, et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715.
38. Hollier BG, Evans K, Mani SA. The epithelial-tomesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009;14:29-43.
39. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-939.
40. Tsuji T, Ibaragi S, Shima K, et al. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 2008;68:10377-10386.
41. Chaffer CL, Brennan JP, Slavin JL, et al. Mesenchymal-toepithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006;66:11271-11278.
42. Aktas B, Tewes M, Fehm T, et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009;11:R46.
43. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791.
44. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-1239.
45. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-377.
46. Stott SL, Lee RJ, Nagrath S, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010;2:25ra23.
47. Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 2010;107:18392-18397.
48. Talasaz AH, Powell AA, Huber DE, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 2009;106:3970-3975.
49. Ameri K, Luong R, Zhang H, et al. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer 2010;102:561-569.
50. Powell AA, Talasaz AH, Zhang H, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012;7:e33788.
51. Zieglschmid V, Hollmann C, Gutierrez B, et al. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res 2005;25:1803-1810.
52. Zieglschmid V, Hollmann C, Böcher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci 2005;42:155-196.
53. Andreopoulou E, Yang LY, Rangel KM, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect? versus Veridex CellSearch? system. Int J Cancer 2012;130:1590-1597.
54. Aktas B, Müller V, Tewes M, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 2011;122:356-360.
55. Kasimir-Bauer S, Hoffmann O, Wallwiener D, et al. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012;14:R15.
56. Rostagno P, Moll J, Bisconte J, et al. Detection of rare circulating breast cancer cells by filtration cytometry and identification by DNA content: sensitivity in an experimental model. Anticancer Res 1997;17:2481-2485.
57. Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000;156:57-63.
58. Pinzani P, Salvadori B, Simi L, et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol 2006;37:711-718.
59. De Giorgi V, Pinzani P, Salvianti F, et al. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 2010;130:2440-2447.
60. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay? and the isolation by size of epithelial tumor cell method. Int J Cancer 2011;129:1651-1660.
61. Adams D, Makarova O, Zu P, et al. Isolation of Circulating Tumor Cells by Size Exclusion using Lithography Fabricated Precision Microfilters. Proceedings 102nd AACR meeting 2011, Orlando, FL, 2011:Abstr 2369.
62. Lin HK, Zheng S, Williams AJ, et al. Portable filterbased microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 2010;16:5011-5018.
63. Das CM, Becker F, Vernon S, et al. Dielectrophoretic segregation of different human cell types on microscope slides. Anal Chem 2005;77:2708-2719.
64. Medoro G, Gross S, Manaresi N, et al. Use of the DEPArray platform to detect, isolate, and molecularly characterize pure tumor cells from peripheral blood samples enriched using the CellSearch system. J Clin Oncol 2011;29:abstr 10616.
65. Alpaugh KR, Bingham C, Fittipaldi P, et al. Mutational analysis of tissue and circulating tumor cells (CTCs) in advanced inflammatory breast cancer (IBC) reveals tumor heterogeneity. Implications for selection of molecular therapies? Cancer Res 2012;72(Suppl).
66. Cristofanilli M, De Gasperis G, Zhang L, et al. Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. Clin Cancer Res 2002;8:615-619.